All Relations between Paroxetine and Olanzapine
| Publication | Sentence | Publish Date | Extraction Date | Species |
|---|---|---|---|---|
| Magdalena Świądro-Piętoń, Dominika Dudek, Renata Wietecha-Posłuszn. Direct Immersion-Solid Phase Microextraction for Therapeutic Drug Monitoring of Patients with Mood Disorders. Molecules (Basel, Switzerland). vol 29. issue 3. 2024-02-10. PMID:38338419. | it has been adapted to identify the most commonly used drugs in mood disorders, including amitriptyline, citalopram, fluoxetine, paroxetine, sertraline, trazodone, duloxetine, venlafaxine, lamotrigine, quetiapine, olanzapine, and mirtazapine. | 2024-02-10 | 2024-02-12 | Not clear |
| Ning Wang, Na Zheng, Mei Dong, Jin H. Paroxetine combined with olanzapine in the treatment of schizophrenia. Pakistan journal of medical sciences. vol 36. issue 3. 2020-09-28. PMID:32292463. | paroxetine combined with olanzapine in the treatment of schizophrenia. | 2020-09-28 | 2023-08-13 | Not clear |
| Ning Wang, Na Zheng, Mei Dong, Jin H. Paroxetine combined with olanzapine in the treatment of schizophrenia. Pakistan journal of medical sciences. vol 36. issue 3. 2020-09-28. PMID:32292463. | to investigate the clinical efficacy of paroxetine combined with olanzapine in the treatment of senile schizophrenia with depression. | 2020-09-28 | 2023-08-13 | Not clear |
| Reiji Yoshimura, Hikaru Hori, Wakako Umene-Nakano, Atsuko Ikenouchi-Sugita, Asuka Katsuki, Kiyokazu Atake, Jun Nakamur. Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder. Therapeutic advances in psychopharmacology. vol 4. issue 3. 2014-07-24. PMID:25057345. | comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder. | 2014-07-24 | 2023-08-13 | Not clear |
| Jiamei Lian, Xu-Feng Huang, Nagesh Pai, Chao Den. Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density. Progress in neuro-psychopharmacology & biological psychiatry. vol 47. 2014-07-02. PMID:23994047. | olanzapine also significantly decreased [(3)h]paroxetine binding to 5-htt in the ventral tegmental area and substantia nigra, however, both olanzapine only and o+b co-treatment did not affect [(3)h]raclopride binding to d2r. | 2014-07-02 | 2023-08-12 | rat |
| Marek Krzystanek, Ewa Krzystanek, Henryk I Trzeciak, Andrzej Małecki, Irena Krupka-Matuszczyk, Małgorzata Janas-Kozik, Janusz K Rybakowsk. Effects of olanzapine and paroxetine on phospholipase D activity in the rat brain. Pharmacological reports : PR. vol 65. issue 3. 2014-04-24. PMID:23950596. | the aim of the study was to evaluate a possible effect of atypical antipsychotic drug, olanzapine (olz), and selective serotonin reuptake inhibitor (ssri) antidepressant, paroxetine (px), on oleate-activated pld activity in plasma membranes isolated from rat brain cortex. | 2014-04-24 | 2023-08-12 | rat |
| Cpt Christopher K Lind, Cpt Lisa R Carchedi, Ltc James J Staudenmeier, Ltc P Carroll J Diebol. Atypical presentations of atypical antipsychotics. Psychiatry (Edgmont (Pa. : Township)). vol 2. issue 6. 2011-07-14. PMID:21152153. | cases reviewed include a schizophrenic male patient whose dose of risperidone was doubled from 6mg to 12mg overnight and developed an acute dystonic reaction; a young male patient with a substance-induced psychosis who unintentionally doubled his ziprasidone dose in 24 hours, resulting in an acute dystonic reaction; a young female patient on paroxetine who also recently started olanzapine and had complaints consistent with akathisia that resolved with treatment; and an adolescent female patient on escitalopram for obsessive-compulsive disorder who after starting aripiprazole developed parkinsonism. | 2011-07-14 | 2023-08-12 | Not clear |
| Shutaro Nakaaki, Yoshie Murata, Toshi A Furukaw. Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder. Psychiatry and clinical neurosciences. vol 62. issue 3. 2008-09-02. PMID:18588607. | efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder. | 2008-09-02 | 2023-08-12 | Not clear |
| Yechiel Levkovitz, Galit Ben-Shushan, Avia Hershkovitz, Roi Isaac, Irit Gil-Ad, Dima Shvartsman, Denise Ronen, Abraham Weizman, Yehiel Zic. Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases. Molecular and cellular neurosciences. vol 36. issue 3. 2008-01-22. PMID:17728140. | here we demonstrate that incubation (1 h) of rat hepatoma fao cells with the ssris paroxetine and sertraline, but not with the atypical antipsychotic drug olanzapine, inhibited the insulin-stimulated tyr phosphorylation of the insulin receptor substrate-1 (irs-1) with half-maximal effects at approximately 10 microm. | 2008-01-22 | 2023-08-12 | rat |
| Ellen R A de Bruijn, Bernard G C Sabbe, Wouter Hulstijn, Gé S F Ruigt, Robbert J Verke. Effects of antipsychotic and antidepressant drugs on action monitoring in healthy volunteers. Brain research. vol 1105. issue 1. 2006-09-29. PMID:16499887. | in the current study, we investigated action monitoring after administration of the classic antipsychotic haloperidol (2.5 mg), the atypical antipsychotic olanzapine (10 mg), and the antidepressant paroxetine (20 mg), a selective serotonin reuptake inhibitor. | 2006-09-29 | 2023-08-12 | human |
| M Bayés, X Rabasseda, J R Prou. Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology. vol 27. issue 5. 2005-09-27. PMID:16082422. | this issue focuses on the following selection of drugs: abiraterone acetate, acyline, adalimumab, adenosine triphosphate, aee-788, aidsvax gp120 b/b, ak-602, alefacept, alemtuzumab, alendronic acid sodium salt, alicaforsen sodium, alprazolam, amdoxovir, amg-162, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, aminophylline hydrate, anakinra, anecortave acetate, anti-ctla-4 mab, apc-8015, aripiprazole, aspirin, atazanavir sulfate, atomoxetine hydrochloride, atorvastatin calcium, atrasentan, ave-5883, azd-2171; betamethasone dipropionate, bevacizumab, bimatoprost, biphasic human insulin (prb), bortezomib, br-a-657, brl-55730, budesonide, busulfan; calcipotriol, calcipotriol/betamethasone dipropionate, calcium folinate, capecitabine, capravirine, carmustine, caspofungin acetate, cefdinir, certolizumab pegol, cg-53135, chlorambucil, ciclesonide, ciclosporin, cisplatin, clofarabine, clopidogrel hydrogensulfate, clozapine, co-trimoxazole, cp-122721, creatine, cy-2301, cyclophosphamide, cypher, cytarabine, cytolin; d0401, darbepoetin alfa, darifenacin hydrobromide, dasb, desipramine hydrochloride, desloratadine, desvenlafaxine succinate, dexamethasone, didanosine, diquafosol tetrasodium, docetaxel, doxorubicin hydrochloride, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; ecallantide, efalizumab, efavirenz, eletriptan, emtricitabine, enfuvirtide, enoxaparin sodium, estramustine phosphate sodium, etanercept, ethinylestradiol, etonogestrel, etonogestrel/ethinylestradiol, etoposide, exenatide; famciclovir, fampridine, febuxostat, filgrastim, fludarabine phosphate, fluocinolone acetonide, fluorouracil, fluticasone propionate, fluvastatin sodium, fondaparinux sodium; gaboxadol, gamma-hydroxybutyrate sodium, gefitinib, gelclair, gemcitabine, gemfibrozil, glibenclamide, glyminox; haloperidol, heparin sodium, hpv 16/hpv 18 vaccine, human insulin, human insulin; icatibant, imatinib mesylate, indium 111 (111in) ibritumomab tiuxetan, infliximab, inkp-100, iodine (i131) tositumomab, iogen, ipratropium bromide, ixabepilone; l-870810, lamivudine, lapatinib, laquinimod, latanoprost, levonorgestrel, licochalcone a, liposomal doxorubicin, lopinavir, lopinavir/ritonavir, lorazepam, lovastatin; maraviroc, maribavir, matuzumab, mdl-100907, melphalan, methotrexate, methylprednisolone, mitomycin, mitoxantrone hydrochloride, mk-0431, mn-001, mrkad5 hiv-1 gag/pol/nef, mrkad5gag, mva.hiva, mva-bn nef, mva-muc1-il-2, mycophenolate mofetil; nelfinavir mesilate, nesiritide, nsc-330507; olanzapine, olmesartan medoxomil, omalizumab, oral insulin, osanetant; pa-457, paclitaxel, paroxetine, paroxetine hydrochloride, pck-3145, peg-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, perillyl alcohol, pexelizumab, pimecrolimus, pitavastatin calcium, porfiromycin, prasterone, prasugrel, pravastatin sodium, prednisone, pregabalin, prinomastat, pro-2000, propofol, prostate cancer vaccine; rasagiline mesilate, rhbmp-2/acs, rhbmp-2/bcp, rhc1, ribavirin, rilpivirine, ritonavir, rituximab, ro-26-9228, rosuvastatin calcium, rosuvastatin sodium, rubitecan; selodenoson, simvastatin, sirolimus, sitaxsentan sodium, sorafenib, ss(dsfv)-pe38, st. john's wort extract, stavudine; tacrolimus, tadalafil, tafenoquine succinate, talaglumetad, tanomastat, taxus, tegaserod maleate, telithromycin, tempol, tenofovir, tenofovir disoproxil fumarate, testosterone enanthate, th-9507, thalidomide, tigecycline, timolol maleate, tiotropium bromide, tipifarnib, torcetrapib, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; valdecoxib, vardenafil hydrochloride hydrate, varenicline, vegf-2 gene therapy, venlafaxine hydrochloride, vildagliptin, vincristine sulfate, voriconazole, vrx-496, vx-385; warfarin sodium; ximelagatran; yttrium 90 (90y) ibritumomab tiuxetan; zanolimumab, zidovudine. | 2005-09-27 | 2023-08-12 | human |
| Gabriele Mas. Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS drugs. vol 18. issue 14. 2004-12-29. PMID:15584771. | pharmacological, efficacy and safety data on drugs acting on serotonin (serotonergic agents such as clomipramine, fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine), on both serotonin and norepinephrine (venlafaxine and mirtazapine), dopamine (dopamine-blocking antipsychotics such as haloperidol and pimozide), and on both serotonin and dopamine (atypical antipsychotics such as clozapine, risperidone, olanzapine, quetiapine and ziprasidone) are presented. | 2004-12-29 | 2023-08-12 | Not clear |
| I L Cha. Olanzapine augmentation in panic disorder: a case report. Pharmacopsychiatry. vol 37. issue 5. 2004-11-02. PMID:15470803. | we report on a man completely remitted from panic disorder after olanzapine and paroxetine combined treatment, and the possible modulating anti-anxiety effect of olanzapine is discussed. | 2004-11-02 | 2023-08-12 | Not clear |
| Vassilis P Kontaxakis, Beata J Havaki-Kontaxaki, Dimitra A Pappa, Dimosthenis E Katritsis, George N Christodoulo. Neuroleptic malignant syndrome after addition of paroxetine to olanzapine. Journal of clinical psychopharmacology. vol 23. issue 6. 2004-03-19. PMID:14624202. | neuroleptic malignant syndrome after addition of paroxetine to olanzapine. | 2004-03-19 | 2023-08-12 | Not clear |
| I Weiner, D Schiller, I Gaisler-Salomon, A Green, D Joe. A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine. Behavioural pharmacology. vol 14. issue 3. 2003-10-14. PMID:12799523. | the typical apd haloperidol (0.1 mg/kg), the atypical apds clozapine (2.5 mg/kg) and olanzapine (0.6 mg/kg), and the antidepressants imipramine (10 mg/kg) and paroxetine (7.0 mg/kg), produced distinct patterns of action in the two tests: haloperidol potentiated li and increased immobility in the fst, clozapine and olanzapine potentiated li and decreased immobility in the fst, and imipramine and paroxetine decreased immobility in the fst and did not potentiate li. | 2003-10-14 | 2023-08-12 | Not clear |
| Giuseppina D'Amico, Clemente Cedro, Maria Rosaria Muscatello, Gianluca Pandolfo, Antonio Enrico Di Rosa, Rocco Zoccali, Diletta La Torre, Concetta D'Arrigo, Edoardo Spin. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Progress in neuro-psychopharmacology & biological psychiatry. vol 27. issue 4. 2003-08-29. PMID:12787848. | the aim of the present study was to investigate the effect of adjunctive olanzapine in patients with obsessive-compulsive disorder (ocd) refractory to paroxetine. | 2003-08-29 | 2023-08-12 | Not clear |
| F König, C von Hippel, T Petersdorff, M Neuhöffer-Weiss, M Wolfersdorf, W P Kaschk. First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression. Neuropsychobiology. vol 43. issue 3. 2001-07-12. PMID:11287796. | first experiences in combination therapy using olanzapine with ssris (citalopram, paroxetine) in delusional depression. | 2001-07-12 | 2023-08-12 | Not clear |
| F König, C von Hippel, T Petersdorff, M Neuhöffer-Weiss, M Wolfersdorf, W P Kaschk. First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression. Neuropsychobiology. vol 43. issue 3. 2001-07-12. PMID:11287796. | in an open prospective study, 26 patients with delusional depression (mood-congruent psychotic features: dsm-iv 296.4) were treated over 5 weeks with a combination of ssri (citalopram, n = 22, or paroxetine, n = 4) and the neuroleptic olanzapine. | 2001-07-12 | 2023-08-12 | Not clear |
| F I Tarazi, K Zhang, R J Baldessarin. Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain. Neuroscience letters. vol 287. issue 2. 2000-08-17. PMID:10854717. | we compared labeling of dopamine (dat) and serotonin (sert) transporter proteins in subregions of rat corpus striatum by quantitative autoradiography with [(3)h]2-beta-carbomethoxy-3-beta-[4'-iodophenyl]tropane ([(3)h]beta-cit) and [(3)h]paroxetine after 28 days of continuous subcutaneous infusion of olanzapine, quetiapine, risperidone, or vehicle controls. | 2000-08-17 | 2023-08-12 | rat |